Effect of SC-40230, a new class I antiarrhythmic agent, on canine ventricular tachycardias
✍ Scribed by S. Garthwaite; Frida Hatley; Leo Frederick; Jeanette Ruby; Chyung Cook
- Publisher
- John Wiley and Sons
- Year
- 1989
- Tongue
- English
- Weight
- 975 KB
- Volume
- 17
- Category
- Article
- ISSN
- 0272-4391
No coin nor oath required. For personal study only.
✦ Synopsis
SC-40230, a-[2-[acetyl( 1 -methylethyl)
amino]ethyl]-tr-(2-chlorophenyl)-l -piperidinebutanamide, a new class I antiarrhythmic agent, was tested for efficacy against coronary ligation-induced arrhythmias and ouabain toxicity arrhythmias in dogs. Doses of 9 mg/kg i.v. and 15, 25, and 35 mgikg p.0. significantly reduced ectopic rate in conscious dogs that had undergone ligation of the left anterior descending coronary artery 24 hr prior to testing. Plasma concentrations of SC-40230 ranging from 3 to 9 pg/ml corresponded with ectopic rate reductions of 10-82% in the coronary ligation model. SC-40230 was well tolerated at all doses tested in the conscious dogs. A 5 mgikg i.v. dose of SC-40230 converted ouabain-induced ventricular tachycardias to normal sinus rhythm in anesthetized dogs. The antiarrhythmic effect of SC-40230 in the ouabain toxicity model was reversed by large ( 5 240 U) doses of insulin. The experiments described in this study demonstrated that SC-40230 is a well-tolerated new class I antiarrhythmic agent with intravenous and oral effectiveness against ventricular arrhythmias.